drugset / Trial / NCT01106859

Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet

NCT01106859

Phase 1 Completed 40 enrolled Transcept Pharmaceuticals
RandomizedCrossoverTriple-blindTreatment

Summary

A study in healthy volunteers of the next morning driving performance after middle-of-the-night dosing of 3.5 mg zolpidem tartrate sublingual tablet, a sleep aid. The next morning driving performance will be measured by taking a standardized driving test.

Timeline

Start
2010-06
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolpidem Small molecule 3.5 mg Other
Comparator Zopiclone Small molecule 7.5 mg Oral

Indications